{"created":"2015-05-14T14:47:21+00:00","modified":"2015-05-14T14:47:21+00:00","valid":{"from":"2013-01-10T20:47:30+00:00","to":"3013-01-10T20:47:30+00:00"},"hreflang":"en","guid":"c512e0be-f584-4153-8824-b15ced06274a","contenttemplated":"[{\"type\":\"text/html\",\"content\":\"<p><strong>CORRECTION: <em>An earlier version of this story incorrectly attributed a comment detailing the factors that go into the retail costs of brand-name drugs. Author Mick Kolassa said the active ingredient in a drug is not what drives costs. The text has been corrected.</em></strong></p>\"},{\"content\":\"<p>If you took an Ambien or similar kind of drug last night to fall sleep, the FDA thinks it still might be making you drowsy this morning -- that&apos;s a safety concern. The agency is <a href=\\\"http://www.nytimes.com/2013/01/11/health/fda-requires-cuts-to-dosages-of-ambien-and-other-sleep-drugs.html\\\" target=\\\"_blank\\\">requiring pharmaceutical companies to cut in half the amount of active ingredient</a> it puts in each dose. So half the dose means half the price, right?</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>Mick Kolassa wrote the book on how pharmaceutical pricing works -- really. It&apos;s called <a href=\\\"http://www.amazon.com/Elements-Pharmaceutical-Pricing-Mick-Kolassa/dp/0789003341\\\" target=\\\"_blank\\\">Elements of Pharmaceutical Pricing</a>. I asked him if cutting in half a pill&apos;s active ingredient translates into a cheaper drug.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>&quot;The short answer to that is, &apos;No&apos;,&quot; says Kolassa.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>According to Kolassa, we’re almost never paying for the active ingredient to begin with.</p>\"},{\"content\":\"<p>But studies say we do pay a lot for research, development, and marketing.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>&quot;If you look at the price of generic Ambien, you can get an idea of what the ingredient cost might be,&quot; Kolassa says.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>The generic runs as little as $10 a month, compared to $200+ for the name brand. While consumers may not see a savings from a weaker dose, Harvard&apos;s Dan Carpenter says drug makers could actually see a loss in the short term.</p>\"},{\"content\":\"<p>&quot;The key effect is the publicity,&quot; says Carpenter.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>He says the FDA&apos;s announcement might cause some patients to switch to a different drug, or quit taking sleep aids all together. In a statement, Ambien&apos;s manufacturer -- Sanofi -- says it is working with the FDA, and stands behind the drug&apos;s safety.  </p>\"}]","published":"2013-01-10T20:47:30+00:00","title":"FDA requires lower-dose sleeping pills","byline":"Jim Burress","description":"So half the dose should mean half the price, right?","itags":["Marketplace Morning Report for Friday, January 11, 2013","Marketplace Morning Report","PMP:Marketplace_PMP","Marketplace","c512e0bef584153f8240b15ced06274a"],"tags":["health care","Health Care","pharmaceuticals","FDA","APM"],"contentencoded":"<div class=\"barn-cleaned\"><p><strong>CORRECTION: <em>An earlier version of this story incorrectly attributed a comment detailing the factors that go into the retail costs of brand-name drugs. Author Mick Kolassa said the active ingredient in a drug is not what drives costs. The text has been corrected.</em></strong></p>\n<p>If you took an Ambien or similar kind of drug last night to fall sleep, the FDA thinks it still might be making you drowsy this morning -- that's a safety concern. The agency is <a href=\"http://www.nytimes.com/2013/01/11/health/fda-requires-cuts-to-dosages-of-ambien-and-other-sleep-drugs.html\" target=\"_blank\">requiring pharmaceutical companies to cut in half the amount of active ingredient</a> it puts in each dose. So half the dose means half the price, right?</p>\n<p>Mick Kolassa wrote the book on how pharmaceutical pricing works -- really. It's called&nbsp;<a href=\"http://www.amazon.com/Elements-Pharmaceutical-Pricing-Mick-Kolassa/dp/0789003341\" target=\"_blank\">Elements of Pharmaceutical Pricing</a>. I asked him if cutting in half a pill's active ingredient translates into a cheaper drug.</p>\n<p>\"The short answer to that is, 'No',\" says Kolassa.</p>\n<p>According to Kolassa, we’re almost never paying for the active ingredient to begin with.</p>\n<p>But studies say we do pay a lot for research, development, and marketing.</p>\n<p>\"If you look at the price of generic Ambien, you can get an idea of what the ingredient cost might be,\" Kolassa says.</p>\n<p>The generic runs as little as $10 a month, compared to $200+ for the name brand. While consumers may not see a savings from a weaker dose, Harvard's Dan Carpenter says drug makers could actually see a loss in the short term.</p>\n<p>\"The key effect is the publicity,\" says Carpenter.</p>\n<p>He says the FDA's announcement might cause some patients to switch to a different drug, or quit taking sleep aids all together. In a statement, Ambien's manufacturer -- Sanofi -- says it is working with the FDA, and stands behind the drug's safety.&nbsp;&nbsp;</p></div>","teaser":"So half the dose should mean half the price, right?","audio":[{"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/57542994.jpg?itok=3ND5zTwq","meta":{"width":"610","height":"340","crop":"primary"},"type":"image/jpeg"},{"type":"audio/mpeg","meta":{"duration_hms":"00:01:24","api":{"href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2013/01/11/marketplace_segment06_20130111","type":"application/json"},"duration":84},"href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2013/01/11/marketplace_segment06_20130111_64.mp3","format":"MP3"}]}